This guidance aims to assist leaders in the development or revision of humanitarian-sector contributions to district-level pandemic preparedness and response planning. It is directly linked to H2P guidance for national-level planning.
Ebola Virus Disease Outbreak Response Plan in West Africa. Annex 2
The EYE strategy is a comprehensive and long-term strategy built on lessons learned that aims at ending yellow fever epidemics by 2026, and consists of three strategic objectives:
protect at-risk populations;
prevent international spread; and
contain outbreaks rapidly.
Health Workers and Health Facilities under Attack 2015, and Early 2016
In case of resistance to rifampicin, fluoroquinolones become the preferred category of second-line drugs. Unfortunately, quinolone-resistant strains of Mycobacterium leprae have also been reported in several countries, probably due to the extensive use of quinolones for treating several types of inf...ections. Clofazimine resistance is still rare but this antimicrobial cannot be given alone
more
The Open Infectious Diseases Journal, 2013, 7, (Suppl 1: M6) 54-59
Bishkek 2015
Accessed: 26.09.2019
Comprehensive Sexuality Education and Adolescents Sexual and Reproductive Health
Aligned to the Lancet Migration Global Statement to include migrants and refugees incountries’response to COVID-19, this update focuses on Mexico’s challenges and opportunities to build an inclusive response that is based on a contextualized adaptation of there commendations published by th...e Lancet Migration. A critical component for this analysis is the recognition of migration as a social determinant of health, which acts as a major risk factor for populations subjected to violence, trauma and forced exile while in the face of a global pandemic.
more
Guide for clinical case management and infection prevention and control during ameasles outbreak. This guide has been developed to reduce the high morbidity and mortality seen in some of the current outbreaks of measles. This short guide outlines practical clinical care interventions and is derived ...from previously published WHO documents.
more
Ukrainian Title: ІНСТРУКЦІЯ ДЛЯ ПІДТРИМКИ ІНТЕГРАЦІЇ ФАРМАЦЕВТИЧНИХ ПРАЦІВНИКІВ-БІЖЕНЦІВ З УКРАЇНИ
This information is based on data provided by the All-Ukrainian Pharmaceutical Chamber (AUPC) to the International Pharmaceutic...al Federation (FIP) in 2017, reviewed by Dr Iryna Vlasenko in April 2022. It is provided to support the integration of refugee pharmacists or pharmacy technicians from Ukraine in other countries. Some data may not be entirely up to date, but will be updated as soon as possible. This document was also developed following the recommendations and inputs by the FIP Forum for Pharmacy Professional Regulators and the FIP Workforce Development Hub.
more
The guidance in this publication consists of generic definitions and methodologies for the characterization of extreme weather and climate events. This publication contribute to ensuring consistent exchange of information that underpins the WMO State of the Climate Reports, Climate Watches, climate ...change studies and other emerging applications.
The purpose of the present guidelines is not to change the practice at the national level. Instead, it provides guidance for generic definitions, which are useful in contributing to WMO State of the Climate reports, climate watches, climate change studies and other emerging applications, including the recently adopted methodology for cataloguing hazardous events (WMO-CHE). These applications require regional and/or international exchange of information on extreme events.
more
This resource pack was developed for the country offices of the World Health Organization and national Public Health institutions, as an overview of the key information needed for advising their Member States in response to questions raised on human health due to influenza outbreaks or detections in... animals. It assembles the available information from WHO, FAO and WOAH, on recommendations and guidelines on influenza that might be relevant to a country experiencing detections or outbreaks of influenza in animals or facing suspicion of human infections with animal-origin influenza viruses. This resource pack updates the information provided in the Summary of Key Information Practical to Countries Experiencing Outbreaks of A(H5N1) and Other Subtypes of Avian Influenza, published in 2016. Additionally, the scope of this current document was broadened to address the risks to public health from all animal influenza viruses, not only avian influenza. Links to existing resources were updated and new resources were added where available.
more
The COVID-19 pandemic has been the biggest disaster in living memory, on almost any measure. More than 6.5 million people are confirmed to have died in less than three years, and the pandemic’s indirect impacts have touched the lives of virtually every community on the planet.
Our World Disasters... Report 2022 focuses on the coronavirus pandemic and preparedness: both the ways preparedness ahead of COVID-19 was inadequate, and how the world can prepare more effectively for future public health emergencies.
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more